↓ Skip to main content

Cochrane Database of Systematic Reviews

Temozolomide for high grade glioma

Overview of attention for article published in Cochrane database of systematic reviews, April 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

news
2 news outlets
facebook
1 Facebook page
wikipedia
7 Wikipedia pages

Citations

dimensions_citation
138 Dimensions

Readers on

mendeley
424 Mendeley
Title
Temozolomide for high grade glioma
Published in
Cochrane database of systematic reviews, April 2013
DOI 10.1002/14651858.cd007415.pub2
Pubmed ID
Authors

Michael G Hart, Ruth Garside, Gabriel Rogers, Ken Stein, Robin Grant

Abstract

High grade glioma (HGG) is an aggressive form of brain cancer. Treatment of HGG usually entails biopsy, or resection if safe, followed by radiotherapy. Temozolomide is a novel oral chemotherapy drug that penetrates into the brain and purportedly has a low incidence of adverse events.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 424 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 <1%
Germany 1 <1%
France 1 <1%
Netherlands 1 <1%
Japan 1 <1%
United States 1 <1%
Unknown 417 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 64 15%
Student > Bachelor 54 13%
Student > Ph. D. Student 44 10%
Student > Doctoral Student 40 9%
Researcher 39 9%
Other 74 17%
Unknown 109 26%
Readers by discipline Count As %
Medicine and Dentistry 142 33%
Biochemistry, Genetics and Molecular Biology 27 6%
Agricultural and Biological Sciences 26 6%
Pharmacology, Toxicology and Pharmaceutical Science 26 6%
Nursing and Health Professions 19 4%
Other 59 14%
Unknown 125 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2021.
All research outputs
#2,442,074
of 25,383,278 outputs
Outputs from Cochrane database of systematic reviews
#5,024
of 12,891 outputs
Outputs of similar age
#19,664
of 200,655 outputs
Outputs of similar age from Cochrane database of systematic reviews
#98
of 261 outputs
Altmetric has tracked 25,383,278 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,891 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 36.1. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 200,655 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 261 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.